Skin Diseases, Genetic News - LARVOL Sigma

Skin Diseases, Genetic

Welcome, Profile Billing Logout

71 Mechanisms of Action

«1 2 3 4 5 6 7 8 91011 12 13 »

|||||||||| Enrollment change: The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) (clinicaltrials.gov) - Feb 4, 2013
P=N/A, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=130 --> 65

|||||||||| Trial termination: Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients (clinicaltrials.gov) - Jan 31, 2013
P3, N=30, Terminated, Sponsor: Hordinsky, Maria K., MD
N=130 --> 65 Suspended --> Terminated; IRB approval has lapsed.

||||||||||  tacrolimus topical / Generic mfg.
New P4 trial:  An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis (clinicaltrials.gov) -  Jan 31, 2013
P4, N=30, Completed,  Sponsor: Janssen-Cilag Ltd.,Thailand

|||||||||| New P3 trial: Emollients in the Management of Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2013
P3, N=347, Completed, Sponsor: Pierre Fabre Medicament

|||||||||| Trial completion: A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Jan 27, 2013
P4, N=20, Completed, Sponsor: Wake Forest School of Medicine
Suspended --> Terminated; IRB approval has lapsed. Active, not recruiting --> Completed

||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Trial withdrawal:  Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome (clinicaltrials.gov) -  Jan 24, 2013
P2, N=0, Withdrawn,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Terminated --> Withdrawn

||||||||||  LEO 29102 / LEO Pharma
Enrollment change:  Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) -  Jan 24, 2013
P1, N=102, Completed,  Sponsor: LEO Pharma
Terminated --> Withdrawn N=72 --> 102

||||||||||  LEO 29102 / LEO Pharma
Trial completion:  Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) -  Jan 24, 2013
P1, N=102, Completed,  Sponsor: LEO Pharma
N=72 --> 102 Recruiting --> Completed

||||||||||  recombinant ectodysplasin A1 (APO200) / Valerio Therap, Pierre Fabre
New P2 trial, IO biomarker:  Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) (clinicaltrials.gov) -  Jan 23, 2013
P2, N=6, Recruiting,  Sponsor: Edimer Pharmaceuticals

||||||||||  fluticasone / Generic mfg.
New P3 trial:  Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children (clinicaltrials.gov) -  Jan 17, 2013
P3, N=100, Recruiting,  Sponsor: Elena Rubio Gomis

||||||||||  MK-8226 / Merck (MSD)
Enrollment open:  A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) -  Jan 1, 2013
P1, N=170, Recruiting,  Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Enrollment closed, IO biomarker: 2ndDermisII: Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis (clinicaltrials.gov) - Dec 18, 2012
P2, N=100, Active, not recruiting, Sponsor: Universidade do Porto
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=36, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Active, not recruiting N=150 --> 36

|||||||||| Trial completion: Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=36, Completed, Sponsor: Edimer Pharmaceuticals
N=150 --> 36 Recruiting --> Completed

|||||||||| Enrollment change: Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=1, Terminated, Sponsor: Stanford University
Recruiting --> Completed N=34 --> 1

|||||||||| New P3 trial: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Dec 11, 2012
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.

|||||||||| Enrollment change: Cooling Pillow for Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=9, Completed, Sponsor: Northwestern University
N=34 --> 1 N=20 --> 9

|||||||||| Trial completion: Cooling Pillow for Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=9, Completed, Sponsor: Northwestern University
N=20 --> 9 Recruiting --> Completed

|||||||||| Trial completion: Acupressure in Pruritus for Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=15, Completed, Sponsor: Northwestern University
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  tacrolimus topical / Generic mfg.
New P4 trial:  Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis (clinicaltrials.gov) -  Dec 6, 2012
P4, N=120, Recruiting,  Sponsor: Astellas Pharma China, Inc.

|||||||||| Enrollment change: Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=35, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed N=100 --> 35

|||||||||| Trial completion: Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=35, Completed, Sponsor: Northwestern University
N=100 --> 35 Active, not recruiting --> Completed

|||||||||| Trial completion: Study of Alwextin® Cream in Treating Epidermolysis Bullosa (clinicaltrials.gov) - Nov 28, 2012
P2, N=8, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change, Adherence: Text Messaging and Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=26, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed N=60 --> 26

|||||||||| Trial completion, Adherence: Text Messaging and Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=26, Completed, Sponsor: Northwestern University
N=60 --> 26 Recruiting --> Completed

||||||||||  Fluzone (influenza vaccine) / Sanofi, Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion:  Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot (clinicaltrials.gov) -  Nov 27, 2012
P0, N=40, Completed,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Completed

||||||||||  MK-8226 / Merck (MSD)
New P1 trial:  A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) -  Nov 20, 2012
P1, N=170, Recruiting,  Sponsor: Merck Sharp & Dohme Corp.

||||||||||  Increlex (mecasermin) / Ipsen
Trial completion:  IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients (clinicaltrials.gov) -  Nov 18, 2012
P=N/A, N=15, Completed,  Sponsor: Bispebjerg Hospital
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Eucrisa (crisaborole) / Pfizer
Trial completion:  Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis (clinicaltrials.gov) -  Nov 14, 2012
P1/2, N=23, Completed,  Sponsor: Anacor Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: Ca-Art-PXE: Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE) (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=71, Completed, Sponsor: University Hospital, Angers
Recruiting --> Completed Recruiting --> Completed

||||||||||  Zyflo (zileuton) / Chiesi
Trial termination:  Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome (clinicaltrials.gov) -  Nov 7, 2012
P1/2, N=3, Terminated,  Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Completed Recruiting --> Terminated; insufficient enrollment

||||||||||  Zyflo (zileuton) / Chiesi
Enrollment change:  Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome (clinicaltrials.gov) -  Nov 7, 2012
P1/2, N=3, Terminated,  Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Terminated; insufficient enrollment N=12 --> 3

|||||||||| Trial completion: Lifting and Tightening of the Face in Subjects With Skin of Darker Color (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=55, Completed, Sponsor: Ulthera, Inc
N=12 --> 3 Terminated --> Completed

||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion:  Rilonacept for Treatment of Familial Mediterranean Fever (FMF) (clinicaltrials.gov) -  Oct 28, 2012
P2, N=14, Completed,  Sponsor: The Cleveland Clinic
Terminated --> Completed Active, not recruiting --> Completed

||||||||||  Lucentis (ranibizumab) / Roche, Novartis
Enrollment change:  FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) -  Oct 23, 2012
P1/2, N=18, Completed,  Sponsor: Manhattan Eye, Ear & Throat Hospital
Active, not recruiting --> Completed N=40 --> 18

||||||||||  Lucentis (ranibizumab) / Roche, Novartis
Trial completion:  FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) -  Oct 23, 2012
P1/2, N=18, Completed,  Sponsor: Manhattan Eye, Ear & Throat Hospital
N=40 --> 18 Recruiting --> Completed

||||||||||  mapracorat (BOL-303242-X) / Bayer
Enrollment change:  HPA Axis Study in Adults (clinicaltrials.gov) -  Oct 21, 2012
P2, N=23, Completed,  Sponsor: Bayer
Recruiting --> Completed N=30 --> 23

||||||||||  mapracorat (BOL-303242-X) / Bayer
Trial completion:  HPA Axis Study in Adults (clinicaltrials.gov) -  Oct 21, 2012
P2, N=23, Completed,  Sponsor: Bayer
N=30 --> 23 Active, not recruiting --> Completed

|||||||||| Trial completion: Ultherapy™ Treatment Following Sculptra® Treatment (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=30, Completed, Sponsor: Ulthera, Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=103, Completed, Sponsor: Ulthera, Inc
Active, not recruiting --> Completed Withheld --> Completed

||||||||||  SB-705498 / GSK
Enrollment change:  Investigation of Topical SB705498 on Healthy Volunteers (clinicaltrials.gov) -  Oct 10, 2012
P1, N=16, Completed,  Sponsor: GlaxoSmithKline
Withheld --> Completed N=20 --> 16

||||||||||  Kineret (anakinra) / SOBI
New P3 trial:  Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (clinicaltrials.gov) -  Oct 10, 2012
P3, N=50, Recruiting,  Sponsor: Sheba Medical Center

||||||||||  SB-705498 / GSK
Trial completion:  Investigation of Topical SB705498 on Healthy Volunteers (clinicaltrials.gov) -  Oct 10, 2012
P1, N=16, Completed,  Sponsor: GlaxoSmithKline
N=20 --> 16 Recruiting --> Completed

||||||||||  Increlex (mecasermin) / Ipsen
Enrollment change:  IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients (clinicaltrials.gov) -  Oct 8, 2012
P=N/A, N=15, Completed,  Sponsor: Bispebjerg Hospital
Recruiting --> Completed N=20 --> 15

||||||||||  difamilast (MM36) / Otsuka, Medimetriks
New P1 trial:  A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis (clinicaltrials.gov) -  Oct 3, 2012
P1, N=92, Completed,  Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion:  Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis (clinicaltrials.gov) -  Oct 1, 2012
P1, N=30, Completed,  Sponsor: Regeneron Pharmaceuticals
N=20 --> 15 Active, not recruiting --> Completed

||||||||||  Ilaris (canakinumab) / Novartis
Trial completion:  The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada (clinicaltrials.gov) -  Sep 29, 2012
P3, N=4, Completed,  Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P2 trial: Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (clinicaltrials.gov) - Sep 19, 2012
P2, N=263, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.

|||||||||| Enrollment open: The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests (clinicaltrials.gov) - Sep 18, 2012
P=N/A, N=160, Recruiting, Sponsor: Meir Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  deferasirox tablet for oral suspension / Generic mfg.
Trial completion:  Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda (clinicaltrials.gov) -  Sep 17, 2012
P3, N=10, Completed,  Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting Recruiting --> Completed